Contribution of FKBP5 Genetic Variation to Gemcitabine Treatment and Survival in Pancreatic Adenocarcinoma

PURPOSE: FKBP51, (FKBP5), is a negative regulator of Akt. Variability in FKBP5 expression level is a major factor contributing to variation in response to chemotherapeutic agents including gemcitabine, a first line treatment for pancreatic cancer. Genetic variation in FKBP5 could influence its funct...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Ellsworth, Katarzyna A., Eckloff, Bruce W., Li, Liang, Moon, Irene, Fridley, Brooke L., Jenkins, Gregory D., Carlson, Erin, Brisbin, Abra, Abo, Ryan, Bamlet, William, Petersen, Gloria, Wieben, Eric D., Wang, Liewei
Formato: Artigo
Idioma:Inglês
Publicado: Public Library of Science 2013
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3731355/
https://ncbi.nlm.nih.gov/pubmed/23936393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0070216
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares